Tumor immune checkpoint therapy (ICT) aims to block immune escape signals between tumor and immune cells. However, low delivery efficiency of immune checkpoint inhibitors (ICIs), narrow single-target approach, and reduced responsiveness notably hinder clinical development of ICT. Here, we developed a nanoliposome-bacteria hybrid system that acts as an antibody (Ab) factory, enabling precise tumor targeting and macrophage activation in hypoxic environments. We reprogrammed attenuated Escherichia coli MG1655 to synthesize CD47 antibodies (aCD47) in response to hypoxic tumor microenvironments while surface conjugating with redox-responsive macrophage colony-stimulating factor-loaded liposomes. This system leverages bacterial tropism to enhance macrophage infiltration and polarization. The low oxygen levels trigger in situ aCD47 expression, blocking the “do not eat me” signal and boosting macrophage antitumor activity. In addition, macrophage antigen presentation activates CD8+CD3+ T cells, amplifying systemic antitumor immunity. Analysis of the gut microbiome shows reduced pathogenicity and improved intestinal tolerance with increased probiotics.

Although chemotherapy is the most common method in clinical therapeutics with a straightforward mechanism, conventional anti-tumor drugs are still almost incapable of preventing the occurrence of tumor metastasis. In this study, we developed a multi-functional drug delivery system EINP@DOX consisting of a tea-derived polyphenol EGCG, iron ions and DOX. The system integrated the functions of tumor inhibition, diagnosis and metastasis prevention to achieve a systematic tumor treatment. The nanoscale size of EINP@DOX facilitated its accumulation in tumor tissues by means of the enhanced permeability and retention (EPR) effect, and it was then transferred to endosomes. The weakly acidic microenvironment in the endosomes of the tumor cells could destroy the coordination structure of EINP@DOX to realize the release of DOX for tumor therapy. Furthermore, the dissociative EGCG played the role of an adjuvant to restrain EMT and down-regulate the MMP levels, which could prevent the occurrence of tumor metastasis. Meanwhile, iron ions as superior magnetic resonance imaging (MRI) contrast agents provided visual evidence for the accurate location of EINP@DOX. In vitro and in vivo studies demonstrated that EINP@DOX showed a remarkable performance in tumor diagnosis and excellent therapeutic efficacy, inhibiting the metastasis of tumor cells effectively at the same time.

In this work, a cellular/intranuclear dual-targeting nanoplatform was designed for tumor photothermal therapy (PTT). As a photo-to-heat nanoheater, a gold nanostar (GNS) was decorated with a nuclear localization sequence (NLS) to form GNS-NLS which possessed nuclear-targeting ability. After that, hyaluronic acid (HA) was coated on the surface of GNS-NLS (GNS-NLS@HA) via electrostatic interaction for tumor cellular recognition and targeting. It was found that by harnessing the recognition of CD44 receptor by HA, GNS-NLS@HA had the ability to target tumor cells accurately, and further be efficaciously internalized into cells with stellate shape. Subsequently, tumor intracellular hyaluronidase (HAase) from the endosome led to the degradation of HA to expose nuclear-targeting nanoheater GNS-NLS, and GNS-NLS was able to enhance PTT efficiency through subcellular nuclear location by a dual-stage near infrared light irradiation strategy. The first stage of light irradiation was of short duration to enhance the subcellular location of the nanoplatform to nuclei, and the second stage of light irradiation was of long duration to achieve admirable photothermal transduction as well as destruction of nuclei. This cellular/intranuclear dual-targeting nanoplatform, GNS-NLS@HA, displayed prominent tumor suppression efficiency both in vitro and in vivo, and inhibited tumor metastasis effectively.

In recent decades, drug self-delivery systems (DSDSs) have appeared with extraordinary superiority for cancer therapy while realizing intracellular delivery without supererogatory drug carriers. Here, we have designed and programmed a novel self-delivery system to realize tumor targeting therapy. The amphiphilic proapoptotic peptide KLAKLAKKLAKLAKGCK(Fmoc)₂ (KLA) was used to form a self-assembled structure (KD) by encapsulating the hydrophobic anticarcinogen doxorubicin (DOX). Then, tumor recognizing hyaluronic acid (HA) was coated on the surface of KD to obtain a tumor targeting self-delivery system (KDH). The protective layer of HA could protect the therapeutic agents from being inactivated during blood circulation, and further specifically recognize tumor cells by the CD44 receptor after KDH had located the tumor regions. Additionally, hyaluronidase (HAase) overexpressed in the endosome of tumor cells could degrade the protective layer of HA and accelerate the liberation of KLA and DOX. The proapoptotic peptide KLA had the ability to locate mitochondria and induce mitochondrial dysfunction; meanwhile the anticarcinogen DOX diffused to the nuclei to inhibit the growth of tumor cells. Both in vitro and in vivo studies identified that our self-delivery system KDH possessed precise tumor targeting, and exhibited fantastic antitumor efficacy as well as negligible side effects.